Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

Malta - İngilizce - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 200 g/l - blood substitutes and perfusion solutions

Malta - İngilizce - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 50 g/l - blood substitutes and perfusion solutions

Malta - İngilizce - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 200 g/l - blood substitutes and perfusion solutions

ABD - İngilizce - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used.1,2,3 acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. human albumin grifols® 20% can be used in such cases.1 human albumin grifols 20% may be of value in the treatment of shock or hypotension in renal dialysis patients.1 preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid.4,5,6 human albumin grifols 20% may be used to treat peripheral edema in patients with acute nephrosis who are refractory to cyclophosphamide, corticosteroid therapy or diuretics.1,2,7 human albumin grifols 20% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when albumin deficit is the result of excessive protein loss, the effect of human albumin grifols 20% administration will be temporary unless the underlying disorder is reversed.8,9,10 septic patients and patients undergoing major surgery may lose more than half of their circulating plasma volume.1,11 treatment with human albumin grifols 20% may be of value in such cases, especially when plasma colloid oncotic pressure is abnormally low.1 in the first 24 hours after thermal injury, large volumes of crystalloids are infused to restore the depleted extracellular fluid volume. beyond 24 hours, human albumin grifols 20% can be used to maintain plasma colloid osmotic pressure.2,12,13 protein loss from the third space due to infection (acute peritonitis, pancreatitis, mediastinitis or extensive cellulitis) may require treatment with an infusion of albumin.14,15 human albumin grifols 20% may be used as a plasma volume expander in fluid management relating to severe forms of ovarian hyperstimulation syndrome.16,17 human albumin grifols 20% is indicated for the treatment of neonatal hyperbilirubinemia. it may be used prior to or during an exchange procedure in an attempt to bind free bilirubin and enhance its excretion.18,19,20 human albumin grifols 20% infusions may be indicated in conjunction with diuretics to correct fluid overload and hypoproteinemia associated with ards.6,21 human albumin grifols 20% may be used to maintain cardiovascular function following removal of large volumes of ascitic fluid after paracentesis due to cirrhotic ascites.2,22,23,24 - hypersensitivity to albumin preparations or to any of the excipients. - severe anemia or cardiac failure with normal or increased intravascular volume. pregnancy category c. animal reproduction studies have not been conducted with human albumin grifols 20%. it is also not known whether human albumin grifols 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. human albumin grifols 20% should be given to a pregnant woman only if clearly needed. no human or animal data. use only if clearly needed. no human or animal data. use only if clearly needed. no human or animal data. use only if clearly needed. no human or animal data. use only if clearly needed.

İsrail - İngilizce - Ministry of Health

cts ltd - human fibrinogen; thrombin - sealant matrix - thrombin 2 iu/cm2; human fibrinogen 5.5 mg/cm2 - human fibrinogen - human fibrinogen - tachosil is indicated for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for sutute support in vascular surgery where standard techniques are insufficient.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human albumin - solution for injection - 10/50 %v/v

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drugs used in diabetes - diabetes mellitus where treatment with insulin is required. insulin human winthrop rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

ABD - İngilizce - NLM (National Library of Medicine)

grifols usa, llc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 0.165 g in 1 ml - gamastan is a human immune globulin indicated for: gamastan is indicated for prophylaxis following exposure to hepatitis a.(1,2) the prophylactic value of gamastan is greatest when given before or soon after exposure to hepatitis a. gamastan is not indicated in persons with clinical manifestations of hepatitis a or in those exposed more than 2 weeks previously. gamastan is indicated to prevent or modify measles in a susceptible person exposed fewer than 6 days previously.(3) a susceptible person is one who has not been vaccinated and has not had measles previously. - gamastan may be especially indicated for susceptible household contacts of measles patients, particularly contacts under 1 year of age, for whom the risk of complications is highest.(3) - gamastan is also indicated for pregnant women without evidence of immunity. - do not give gamastan and measles vaccine at the same time. if a child is older than 12 months and has received gamastan, give measles vaccine about five months later when the measles a

ABD - İngilizce - NLM (National Library of Medicine)

sanofi pasteur inc. - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies immune globulin (human) heat treated, imogam rabies – ht, in conjunction with the standard series of rabies vaccine vaccinations, is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with rabies vaccine. previously immunized persons are those who have had a documented rabies virus neutralizing antibody titer and who have completed one of the recommended regimens (pre-exposure or post-exposure) with a cell culture vaccine or another vaccine. administer only vaccine to these persons (i.e., post-exposure for a person previously vaccinated). (1) inject imogam rabies – ht, as promptly as possible after exposure, along with the first dose of vaccine. if initiation of treatment is delayed for any reason, still administer imogam rabies – ht and the first dose of vaccine, regardless of the interval between exposure and treatment. if rabies immune globulin (human) was not administered when vaccination was begun